| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037678066 |
| P356 | DOI | 10.1038/NATURE05355 |
| P698 | PubMed publication ID | 17183313 |
| P5875 | ResearchGate publication ID | 5552753 |
| P2093 | author name string | George D Yancopoulos | |
| Nicholas W Gale | |||
| Gavin Thurston | |||
| Sandra Coetzee | |||
| Christopher Daly | |||
| Irene Noguera-Troise | |||
| Hsin Chieh Lin | |||
| Nicholas J Papadopoulos | |||
| Pat Boland | |||
| P2860 | cites work | Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. | Q37594746 |
| Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors | Q40272804 | ||
| The Nrarp gene encodes an ankyrin-repeat protein that is transcriptionally regulated by the notch signaling pathway | Q40758061 | ||
| A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling | Q43972008 | ||
| VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets | Q79995569 | ||
| Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1 | Q83005184 | ||
| VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Notch signaling: cell fate control and signal integration in development | Q27861061 | ||
| High-throughput engineering of the mouse genome coupled with high-resolution expression analysis | Q28202486 | ||
| HES and HERP families: multiple effectors of the Notch signaling pathway | Q28205103 | ||
| Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression | Q28216123 | ||
| Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants | Q28505269 | ||
| Dosage-sensitive requirement for mouse Dll4 in artery development | Q28587979 | ||
| Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 | ||
| Angiogenesis in life, disease and medicine | Q29614539 | ||
| Vascular-specific growth factors and blood vessel formation | Q29614780 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis | Q34110003 | ||
| Notch signaling in primary endothelial cells | Q34207008 | ||
| Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function | Q34456711 | ||
| Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. | Q34520330 | ||
| Tumor angiogenesis and accessibility: role of vascular endothelial growth factor | Q35040013 | ||
| Nrarp is a novel intracellular component of the Notch signaling pathway | Q35080412 | ||
| Notch function in the vasculature: insights from zebrafish, mouse and man. | Q35677633 | ||
| Vascular endothelial growth factor as a target for anticancer therapy | Q35792723 | ||
| Notch signaling during vascular development | Q35876755 | ||
| The role of notch in modeling and maintaining the vasculature | Q36067007 | ||
| Lessons from phase III clinical trials on anti-VEGF therapy for cancer | Q36366446 | ||
| P433 | issue | 7122 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1032-1037 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis | |
| P478 | volume | 444 |
| Q83899710 | A 3-D model of tumor progression based on complex automata driven by particle dynamics |
| Q35927467 | A Mathematical Model Coupling Tumor Growth and Angiogenesis |
| Q63916383 | A Potential Role for Exosomal Translationally Controlled Tumor Protein Export in Vascular Remodeling in Pulmonary Arterial Hypertension |
| Q36666096 | A Role for PPARbeta/delta in Tumor Stroma and Tumorigenesis. |
| Q43872977 | A disulfide-constrained miniprotein with striking tumor-binding specificity developed by ribosome display |
| Q36949613 | A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis |
| Q37299473 | A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells |
| Q37111141 | A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). |
| Q42010099 | A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis |
| Q37708831 | A three-molecule score based on Notch pathway predicts poor prognosis in non-metastasis clear cell renal cell carcinoma |
| Q37111322 | ADAM proteases: ligand processing and modulation of the Notch pathway |
| Q38888721 | AIBP Limits Angiogenesis Through γ-Secretase-Mediated Upregulation of Notch Signaling. |
| Q33662919 | ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer |
| Q43106806 | Achieving tissue specific levels of angiogenesis: Not(ch) a big deal! |
| Q37699173 | Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies. |
| Q39553893 | Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. |
| Q48854018 | Activation of multiple angiogenic signaling pathways in hemangiopericytoma |
| Q33693793 | Adrenomedullin as a therapeutic target in angiogenesis |
| Q45065026 | Agent-based computational model of retinal angiogenesis simulates microvascular network morphology as a function of pericyte coverage. |
| Q27334865 | Agent-based model of angiogenesis simulates capillary sprout initiation in multicellular networks |
| Q35247504 | An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factors |
| Q30485390 | Analysis of pairwise cell interactions using an integrated dielectrophoretic-microfluidic system |
| Q41591243 | Analysis of the microvascular morphology and hemodynamics of breast cancer in mice using SPring-8 synchrotron radiation microangiography |
| Q33598375 | Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance |
| Q34423550 | Angiogenesis - still a worthwhile target for breast cancer therapy? |
| Q37504362 | Angiogenesis as a therapeutic target in malignant gliomas |
| Q34056376 | Angiogenesis inhibitors: current strategies and future prospects |
| Q36014526 | Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. |
| Q34624256 | Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular quiescence by inducing delta-like 4 expression through AKT-mediated activation of beta-catenin |
| Q42466000 | Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method |
| Q38540667 | Anti-DLL4, a cancer therapeutic with multiple mechanisms of action |
| Q41258130 | Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. |
| Q26775947 | Anti-angiogenic alternatives to VEGF blockade |
| Q41597464 | Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation |
| Q38757723 | Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility |
| Q34515465 | Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches |
| Q37614203 | Antiangiogenic therapies for high-grade glioma |
| Q64057935 | Arsenic Trioxide Suppresses Tumor Growth through Antiangiogenesis via Notch Signaling Blockade in Small-Cell Lung Cancer |
| Q28506090 | Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis |
| Q46029432 | Atypical E2Fs inhibit tumor angiogenesis. |
| Q37746510 | Axon guidance molecules in vascular patterning |
| Q28483874 | Biochemical characterization and cellular effects of CADASIL mutants of NOTCH3 |
| Q40263189 | Biodegradable Polymeric Microsphere-Based Drug Delivery for Inductive Browning of Fat. |
| Q35611763 | Biological properties of extracellular vesicles and their physiological functions. |
| Q35216301 | Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. |
| Q37815281 | Biomarkers to predict the clinical efficacy of bevacizumab in cancer |
| Q39901953 | Blockade of Notch signaling in tumor-bearing mice may lead to tumor regression, progression, or metastasis, depending on tumor cell types |
| Q36733439 | Blockade of individual Notch ligands and receptors controls graft-versus-host disease |
| Q28285842 | Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation |
| Q89995945 | Blood Vessel Patterning on Retinal Astrocytes Requires Endothelial Flt-1 (VEGFR-1) |
| Q30831553 | Blood flow controls bone vascular function and osteogenesis. |
| Q37328390 | Blood-based biomarkers for the optimization of anti-angiogenic therapies |
| Q33869431 | Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis. |
| Q33760569 | Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors |
| Q82372171 | Brain pericytes: emerging concepts and functional roles in brain homeostasis |
| Q37502702 | Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. |
| Q27002903 | Broad targeting of angiogenesis for cancer prevention and therapy |
| Q38203137 | CCM1 and the second life of proteins in adhesion complexes. |
| Q37031812 | CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury |
| Q33891662 | CD248 facilitates tumor growth via its cytoplasmic domain. |
| Q58781616 | Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu |
| Q44853108 | Cancer immunology. Identifying the infiltrators |
| Q37796629 | Cancer stem cells: a new framework for the design of tumor therapies. |
| Q37785194 | Canonical and non-canonical Notch ligands |
| Q34341494 | Cellular and physical mechanisms of branching morphogenesis |
| Q38687397 | Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use. |
| Q33531734 | Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors |
| Q59082154 | Chronic DLL4 blockade induces vascular neoplasms |
| Q38645097 | Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review). |
| Q37114635 | Clinical implications of DLL4 expression in gastric cancer |
| Q37766940 | Clinical trials with anti-angiogenic agents in hematological malignancies |
| Q41641853 | Clock controls angiogenesis. |
| Q36931174 | Collagen represses canonical Notch signaling and binds to Notch ectodomain |
| Q33752236 | Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis |
| Q34476250 | Combination of phage display and molecular grafting generates highly specific tumor-targeting miniproteins |
| Q42284431 | Combining virotherapy and angiotherapy for the treatment of breast cancer. |
| Q34078467 | Comparison of manual and digital microvascular density counting of RECK expression in glioma |
| Q34533929 | Context- and cell-dependent effects of Delta-like 4 targeting in the bone marrow microenvironment |
| Q52563257 | Contribution of Tumor Endothelial Cells in Cancer Progression. |
| Q42909820 | Control of endothelial sprouting by a Tel–CtBP complex |
| Q37672654 | Controlling escape from angiogenesis inhibitors |
| Q36184318 | Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells |
| Q89637491 | Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis |
| Q53280318 | Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth. |
| Q51843632 | Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. |
| Q57109688 | Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMT |
| Q38088366 | Current status and future prospects for anti-angiogenic therapies in cancer. |
| Q36541012 | Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling |
| Q47144065 | DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer. |
| Q54186977 | DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice. |
| Q35893143 | Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer |
| Q34990930 | Defects in hepatic Notch signaling result in disruption of the communicating intrahepatic bile duct network in mice |
| Q35140965 | Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures |
| Q34368177 | Delta-like 4 inhibits choroidal neovascularization despite opposing effects on vascular endothelium and macrophages |
| Q35538051 | Delta-like 4 mRNA is regulated by adjacent natural antisense transcripts |
| Q36249368 | Delta-like 4/Notch signaling promotes Apc Min/+ tumor initiation through angiogenic and non-angiogenic related mechanisms |
| Q24685542 | Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting |
| Q48268782 | Delta-like ligand 4 correlates with endothelial proliferation and vessel maturation in human malignant glioma |
| Q58740348 | Delta-like ligand 4 in hepatocellular carcinoma intrinsically promotes tumour growth and suppresses hepatitis B virus replication |
| Q33638230 | Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. |
| Q34542176 | Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation |
| Q39456092 | Delta-like ligand 4-notch blockade and tumor radiation response |
| Q34427294 | Delta-like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinoma |
| Q89615461 | Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial |
| Q35941519 | Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice |
| Q41718098 | Detrimental effect of Hypoxia-inducible factor-1α-induced autophagy on multiterritory perforator flap survival in rats |
| Q36828050 | Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition |
| Q27023250 | Developmental and pathological angiogenesis in the central nervous system |
| Q48009901 | Dibenzazepine-Loaded Nanoparticles Induce Local Browning of White Adipose Tissue to Counteract Obesity |
| Q24309476 | Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis |
| Q28512115 | Dll1- and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells |
| Q36971300 | Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth |
| Q36843739 | Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth |
| Q35418092 | Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts |
| Q37933528 | Dll4-Notch signaling as a therapeutic target in tumor angiogenesis |
| Q33818037 | Dll4-Notch signaling determines the formation of native arterial collateral networks and arterial function in mouse ischemia models |
| Q35946087 | Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice |
| Q38151514 | Dll4-Notch signaling in regulation of tumor angiogenesis |
| Q30571193 | Dll4-containing exosomes induce capillary sprout retraction in a 3D microenvironment |
| Q27345016 | Dll4-notch signalling blockade synergizes combined ultrasound-stimulated microbubble and radiation therapy in human colon cancer xenografts |
| Q39305041 | Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology |
| Q34796840 | Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4. |
| Q49384248 | Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling |
| Q38645902 | Dynamics of angiogenesis in ischemic areas of the infarcted heart |
| Q48197407 | EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway |
| Q35776390 | EGFL7: a unique angiogenic signaling factor in vascular development and disease |
| Q41903209 | Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice |
| Q90388017 | Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis |
| Q85812162 | Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma |
| Q40029207 | Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers |
| Q43900208 | Elevated expression of notch1 is associated with metastasis of human malignancies. |
| Q30487167 | Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting |
| Q37042648 | Embryological Origin of Human Smooth Muscle Cells Influences Their Ability to Support Endothelial Network Formation |
| Q37231575 | Endogenous endothelial cell signaling systems maintain vascular stability |
| Q33917562 | Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis |
| Q36306542 | Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo |
| Q41166648 | Endothelial Dll4-Notch signaling in tumor microenvironment: is there any hidden therapeutic opportunity? |
| Q35858012 | Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes |
| Q38849027 | Endothelial Jagged1 promotes solid tumor growth through both pro-angiogenic and angiocrine functions. |
| Q34408556 | Endothelial Kruppel-like factor 4 regulates angiogenesis and the Notch signaling pathway |
| Q37091548 | Endothelial Notch activity promotes angiogenesis and osteogenesis in bone |
| Q48116044 | Endothelial Notch signalling limits angiogenesis via control of artery formation. |
| Q36193529 | Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression |
| Q92889943 | Endothelial ZEB1 promotes angiogenesis-dependent bone formation and reverses osteoporosis |
| Q34777219 | Endothelial cell-initiated extravasation of cancer cells visualized in zebrafish |
| Q42174577 | Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells |
| Q34572680 | Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. |
| Q34473290 | Endothelial cells provide a notch-dependent pro-tumoral niche for enhancing breast cancer survival, stemness and pro-metastatic properties |
| Q35592719 | Endothelial cells-targeted soluble human Delta-like 4 suppresses both physiological and pathological ocular angiogenesis |
| Q48162975 | Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease |
| Q37271066 | Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis |
| Q36498075 | Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling |
| Q38939975 | Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis |
| Q28267098 | Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development |
| Q90371899 | Endothelial lineage-specific interaction of Mycobacterium tuberculosis with the blood and lymphatic systems |
| Q37489539 | Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells. |
| Q36279079 | Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model |
| Q38842539 | EphrinB2/EphB4 pathway in postnatal angiogenesis: a potential therapeutic target for ischemic cardiovascular disease. |
| Q28067753 | Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells |
| Q34031959 | Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis |
| Q24632791 | Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma |
| Q37157213 | Exercise training and peripheral arterial disease |
| Q35985220 | Expanding role of delta-like 4 mediated notch signaling in cardiovascular and metabolic diseases |
| Q37424106 | Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer |
| Q45848377 | Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma |
| Q33745294 | Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer |
| Q51981848 | Expression pattern of Dll4 during chick embryogenesis. |
| Q40236299 | Expressions of OCT4, Notch1 and DLL4 and their clinical implications in epithelial ovarian cancer |
| Q27000351 | Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. |
| Q42158004 | FAK-heterozygous mice display enhanced tumour angiogenesis |
| Q36382073 | Fellow travellers: emergent properties of collective cell migration |
| Q30276870 | Flt-1 (VEGFR-1) coordinates discrete stages of blood vessel formation |
| Q42409352 | Flt-1 (vascular endothelial growth factor receptor-1) is essential for the vascular endothelial growth factor-Notch feedback loop during angiogenesis |
| Q35958147 | Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer |
| Q37758401 | Formation of cardiovascular tubes in invertebrates and vertebrates. |
| Q27004534 | From fly wings to targeted cancer therapies: a centennial for notch signaling |
| Q37286610 | Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. |
| Q61814546 | Gamma-Secretase Inhibitor, DAPT, Prevents the Development of Retinopathy of Prematurity in a Rat Model by Regulating the Delta-Like Ligand 4/Notch Homolog-1 (DLL4/Notch-1) Pathway |
| Q39307641 | Gamma-secretase inhibitor DAPT suppresses glioblastoma growth via uncoupling of tumor vessel density from vessel function |
| Q28477769 | Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion |
| Q38618901 | Generation of a functional humanized Delta-like ligand 4 transgenic mouse model |
| Q37415954 | Glioblastoma multiforme therapy and mechanisms of resistance. |
| Q38216381 | Graft microvascular disease in solid organ transplantation |
| Q37326075 | Griffonia simplicifolia isolectin B4 identifies a specific subpopulation of angiogenic blood vessels following contusive spinal cord injury in the adult mouse |
| Q41884005 | HIF-1alpha versus HIF-2alpha in endothelial cells and vascular functions: is there a master in angiogenesis regulation? |
| Q37333482 | Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. |
| Q94562195 | Heritable modifiers of the tumor microenvironment influence nanoparticle uptake, distribution and response to photothermal therapy |
| Q82359253 | Heterogeneity of vascular and progenitor cell compartments in tumours from MMTV-PyVmT transgenic mice during mammary cancer progression |
| Q44405105 | High Jagged1 Expression Predicts Poor Outcome in Clear Cell Renal Cell Carcinoma |
| Q36150889 | High delta-like ligand 4 (DLL4) is correlated with peritumoral brain edema and predicts poor prognosis in primary glioblastoma |
| Q91756542 | High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer |
| Q54569303 | High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer. |
| Q64076263 | High mitogenic stimulation arrests angiogenesis |
| Q39593637 | High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. |
| Q37269906 | Histone H2AX is integral to hypoxia-driven neovascularization |
| Q59792628 | Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target? |
| Q38752236 | Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer. |
| Q91081552 | Human blood vessel organoids as a model of diabetic vasculopathy |
| Q33354053 | Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy |
| Q39016724 | IFNγ-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4. |
| Q34760267 | IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms |
| Q35040504 | Identification and functional analysis of endothelial tip cell-enriched genes |
| Q27014031 | Immunotargeting of cancer stem cells |
| Q42000250 | Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer |
| Q37187681 | Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme |
| Q52715373 | Inactivation of the serine protease HTRA1 inhibits tumor growth by deregulating angiogenesis. |
| Q35757896 | Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas |
| Q33922852 | Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B |
| Q37050459 | Influence of up-regulation of Notch ligand DLL4 on biological behaviors of human gastric cancer cells |
| Q55375766 | Inhibition of Dll4/Notch1 pathway promotes angiogenesis of Masquelet's induced membrane in rats. |
| Q33911184 | Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature |
| Q39129297 | Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability |
| Q36146211 | Inhibition of delta-like ligand 4 induces luteal hypervascularization followed by functional and structural luteolysis in the primate ovary. |
| Q30495907 | Inhibition of delta-like-4-mediated signaling impairs reparative angiogenesis after ischemia |
| Q36905854 | Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis |
| Q39885220 | Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma |
| Q39094806 | Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis |
| Q39132553 | Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells |
| Q41876373 | Integration of angiogenesis modules at multiple scales: from molecular to tissue |
| Q90685529 | Intriguing Roles for Endothelial ADAM10/Notch Signaling in the Development of Organ-Specific Vascular Beds |
| Q37132158 | Intrinsic selectivity of Notch 1 for Delta-like 4 over Delta-like 1. |
| Q93044894 | Intussusceptive Vascular Remodeling Precedes Pathological Neovascularization |
| Q33305435 | Involvement of notch signaling in wound healing |
| Q33651585 | Involvement of the Reck tumor suppressor protein in maternal and embryonic vascular remodeling in mice |
| Q36020230 | In vitro selection technologies to enhance biomaterial functionality |
| Q34973725 | Isolation and function of mouse tissue resident vascular precursors marked by myelin protein zero |
| Q35895576 | Jagged mediates differences in normal and tumor angiogenesis by affecting tip-stalk fate decision. |
| Q28117817 | KCTD10 is involved in the cardiovascular system and Notch signaling during early embryonic development |
| Q33509506 | KSHV manipulates Notch signaling by DLL4 and JAG1 to alter cell cycle genes in lymphatic endothelia |
| Q47159862 | Leptin-induced transphosphorylation of vascular endothelial growth factor receptor increases Notch and stimulates endothelial cell angiogenic transformation |
| Q26851470 | Leukocyte driven-decidual angiogenesis in early pregnancy |
| Q34556483 | Leukotriene B4 antagonism ameliorates experimental lymphedema |
| Q89662454 | Linc-OIP5 in the breast cancer cells regulates angiogenesis of human umbilical vein endothelial cells through YAP1/Notch/NRP1 signaling circuit at a tumor microenvironment |
| Q33393502 | Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli |
| Q37843945 | Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma |
| Q90264830 | Low dosage of arsenic trioxide (As2O3) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis |
| Q34141670 | Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis |
| Q38192927 | Lymphangiogenic factors, mechanisms, and applications |
| Q34446620 | MOSAIC: a multiscale model of osteogenesis and sprouting angiogenesis with lateral inhibition of endothelial cells |
| Q52721396 | MPDZ promotes DLL4-induced Notch signaling during angiogenesis. |
| Q34731745 | MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model |
| Q35256272 | MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. |
| Q37363751 | Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature |
| Q36774809 | Matrix Gla protein reinforces angiogenic resolution |
| Q41832788 | Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. |
| Q36295477 | Mechanisms of glioma-associated neovascularization |
| Q26824557 | Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme |
| Q34972161 | Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates |
| Q38196881 | Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications |
| Q37785192 | Mechanistic insights into Notch receptor signaling from structural and biochemical studies |
| Q30439221 | Metastasis: a therapeutic target for cancer |
| Q58077846 | MicroRNA-30a as a candidate underlying sex-specific differences in neonatal hyperoxic lung injury: Implications for BPD |
| Q36787043 | Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells |
| Q89112255 | Mimetic peptide of ubiquitin-interacting motif of epsin as a cancer therapeutic-perspective in brain tumor therapy through regulating VEGFR2 signaling |
| Q34241543 | Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. |
| Q35785994 | Mirtron microRNA-1236 inhibits VEGFR-3 signaling during inflammatory lymphangiogenesis |
| Q34172388 | Modulating Notch signaling to enhance neovascularization and reperfusion in diabetic mice. |
| Q50423780 | Molecular Regulation of Sprouting Angiogenesis. |
| Q39786861 | Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. |
| Q37863911 | Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting |
| Q27007664 | Molecular control of endothelial cell behaviour during blood vessel morphogenesis |
| Q84736698 | Molecular mechanisms of tumor angiogenesis |
| Q33639474 | Molecular mediators of angiogenesis |
| Q38267262 | Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer |
| Q29616150 | Molecular regulation of angiogenesis and lymphangiogenesis |
| Q38093654 | Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. |
| Q37736281 | Molecular therapeutic targets for glioma angiogenesis |
| Q47409939 | Molecular weight fibrinogen variants alter gene expression and functional characteristics of human endothelial cells |
| Q38206818 | Monoclonal antibodies against human cancer stem cells |
| Q36335923 | Motif mimetic of epsin perturbs tumor growth and metastasis |
| Q59791901 | Moving Breast Cancer Therapy up a Notch |
| Q37086837 | Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer |
| Q91993914 | Multi-Faceted Notch in Allergic Airway Inflammation |
| Q64119426 | Multifactorial Contribution of Notch Signaling in Head and Neck Squamous Cell Carcinoma |
| Q36772312 | Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis |
| Q30432668 | Multiscale models of angiogenesis |
| Q35581299 | NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth |
| Q37439353 | NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. |
| Q37684455 | NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype |
| Q48209273 | Nanocarrier based approaches for targeting breast cancer stem cells. |
| Q38005043 | Neuronal stem cells in the central nervous system and in human diseases |
| Q41669132 | Neurovascular patterning cues and implications for central and peripheral neurological disease |
| Q33619010 | Neutralizing endogenous VEGF following traumatic spinal cord injury modulates microvascular plasticity but not tissue sparing or functional recovery |
| Q38234993 | New Approaches to Target T-ALL. |
| Q37958937 | New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis |
| Q33956040 | New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. |
| Q38673797 | Non-canonical NOTCH3 signalling limits tumour angiogenesis. |
| Q42410358 | Notch Receptor-Ligand Engagement Maintains Hematopoietic Stem Cell Quiescence and Niche Retention |
| Q37802720 | Notch Signaling Pathway as a Therapeutic Target in Breast Cancer |
| Q46795621 | Notch Signaling in Development, Tissue Homeostasis, and Disease |
| Q36861805 | Notch Signaling in the Vasculature |
| Q37360514 | Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis. |
| Q37952793 | Notch and inflammatory T-cell response: new developments and challenges |
| Q38074776 | Notch as a hub for signaling in angiogenesis. |
| Q38268444 | Notch functions in developmental and tumour angiogenesis by diverse mechanisms |
| Q30426785 | Notch inhibition as a promising new approach to cancer therapy |
| Q30426621 | Notch inhibitors as a new tool in the war on cancer: a pathway to watch |
| Q34330869 | Notch inhibitors for cancer treatment |
| Q36079508 | Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders |
| Q41967564 | Notch modulates VEGF action in endothelial cells by inducing Matrix Metalloprotease activity |
| Q36602728 | Notch receptor and effector expression in von Hippel-Lindau disease-associated central nervous system hemangioblastomas |
| Q27023341 | Notch receptor-ligand binding and activation: insights from molecular studies |
| Q42542271 | Notch regulation of hematopoiesis, endothelial precursor cells, and blood vessel formation: orchestrating the vasculature |
| Q37861206 | Notch regulation of tumor angiogenesis |
| Q36091310 | Notch signaling and Notch signaling modifiers |
| Q49375412 | Notch signaling controls sprouting angiogenesis of endometriotic lesions |
| Q36137696 | Notch signaling in developmental and tumor angiogenesis |
| Q33747041 | Notch signaling in glioblastoma: a developmental drug target? |
| Q35719022 | Notch signaling in ocular vasculature development and diseases |
| Q27001047 | Notch signaling in prostate cancer: a moving target |
| Q38805816 | Notch signaling in regulating angiogenesis in a 3D biomimetic environment |
| Q37785204 | Notch signaling in solid tumors. |
| Q37256455 | Notch signaling regulates tumor angiogenesis by diverse mechanisms |
| Q48268613 | Notch signaling triggered via the ligand DLL4 impedes M2 macrophage differentiation and promotes their apoptosis. |
| Q41166603 | Notch signaling: a hero or villain in the war against cancer? |
| Q26765033 | Notch signaling: its roles and therapeutic potential in hematological malignancies |
| Q43100497 | Notch signaling: mediator and therapeutic target of bone metastasis |
| Q37169972 | Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition |
| Q37954986 | Notch signalling in cancer progression and bone metastasis |
| Q33649282 | Notch signalling in ischaemia-induced angiogenesis. |
| Q37867484 | Notch signalling in solid tumours: a little bit of everything but not all the time |
| Q35463593 | Notch suppresses angiogenesis and progression of hepatic metastases |
| Q53078939 | Notch-1 mediates endothelial cell activation and invasion in psoriasis. |
| Q28587298 | Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling |
| Q37460657 | Notch1 Deficiency Results in Decreased Inflammation during Wound Healing and Regulates Vascular Endothelial Growth Factor Receptor-1 and Inflammatory Cytokine Expression in Macrophages |
| Q30497988 | Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. |
| Q45524907 | Notch1 mediates visfatin-induced FGF-2 up-regulation and endothelial angiogenesis |
| Q38988209 | Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells |
| Q35963167 | Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth |
| Q36816068 | Notch4 is required for tumor onset and perfusion |
| Q26858778 | Notch: a key regulator of tumor angiogenesis and metastasis |
| Q38324552 | Notching on Cancer's Door: Notch Signaling in Brain Tumors |
| Q47827202 | Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways. |
| Q37325086 | Novel anti-angiogenic therapies for malignant gliomas |
| Q37657105 | Novel insights into the differential functions of Notch ligands in vascular formation |
| Q37984612 | Novel targets for VEGF-independent anti-angiogenic drugs. |
| Q39857255 | Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues |
| Q51866669 | Ongoing Dll4-Notch signaling is required for T-cell homeostasis in the adult thymus. |
| Q28542577 | Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling |
| Q28506962 | Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos |
| Q44520861 | Overexpression of factor inhibiting HIF-1 enhances vessel maturation and tumor growth via platelet-derived growth factor-C. |
| Q37125627 | Pancreatic carcinogenesis |
| Q36849240 | Perivascular instruction of cell genesis and fate in the adult brain |
| Q37863614 | Perspectives on lymphangiogenesis and angiogenesis in cancer |
| Q52373664 | Pharmacological targets of breast cancer stem cells: a review. |
| Q47943403 | Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. |
| Q36268182 | PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors |
| Q42555333 | Prevalence of intrinsic disorder in the intracellular region of human single-pass type I proteins: the case of the notch ligand Delta-4. |
| Q84801828 | Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival |
| Q79897707 | Promoting angiogenesis to a fault |
| Q37315917 | Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling |
| Q44040143 | Protein kinase D2 and heat shock protein 90 beta are required for BCL6-associated zinc finger protein mRNA stabilization induced by vascular endothelial growth factor-A. |
| Q92659238 | Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis |
| Q35516131 | Quantitative assessment of angiogenesis, perfused blood vessels and endothelial tip cells in the postnatal mouse brain. |
| Q83349471 | RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model |
| Q39226446 | Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models |
| Q36949857 | Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways |
| Q91678256 | Regulation of Notch signaling in the developing Drosophila eye by a T-box containing transcription factor, Dorsocross |
| Q37590325 | Regulation of angiogenesis in malignancies associated with Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus |
| Q38101895 | Regulation of endothelial cell differentiation and specification |
| Q33791749 | Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration. |
| Q37473177 | Renal toxicity of targeted therapies |
| Q38232852 | Resistance to antiangiogenic therapies |
| Q58557198 | Restriction of drug transport by the tumor environment |
| Q38700730 | Role of Delta-Notch signaling in cerebral cavernous malformations |
| Q41093114 | Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth |
| Q38866740 | Role of G protein-coupled receptor kinase 2 in tumoral angiogenesis |
| Q34697373 | Role of Notch and its oncogenic signaling crosstalk in breast cancer |
| Q37606133 | Role of Notch signaling in colorectal cancer |
| Q34728237 | Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. |
| Q33767742 | Role of mesenchymal stem cells, their derived factors, and extracellular vesicles in liver failure |
| Q39192384 | Role of the Notch signaling in cholangiocarcinoma. |
| Q34428786 | SIRT1 regulates endothelial Notch signaling in lung cancer |
| Q89168207 | Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment |
| Q89587286 | Shaping of the Tumor Microenvironment by Notch Signaling |
| Q37705914 | Signaling circuitry in vascular morphogenesis |
| Q37972805 | Signaling pathways governing tumor angiogenesis |
| Q26996608 | Signaling pathways in the development of infantile hemangioma |
| Q39569424 | Silencing of hHS6ST2 inhibits progression of pancreatic cancer through inhibition of Notch signalling |
| Q37141599 | Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis |
| Q41956646 | Simultaneous targeted activation of Notch1 and Vhl-disruption in the kidney proximal epithelial tubular cells in mice |
| Q53082876 | Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. |
| Q35533533 | Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor |
| Q27324465 | Stability and function of adult vasculature is sustained by Akt/Jagged1 signalling axis in endothelium |
| Q42098324 | Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades |
| Q57461122 | Staphylococcus aureus alpha toxin activates Notch in vascular cells |
| Q85579065 | State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer |
| Q36845727 | Statistical platform to discern spatial and temporal coordination of endothelial sprouting. |
| Q38844258 | Study of angiogenic signaling pathways in hemangioblastoma |
| Q36249525 | Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo |
| Q24324662 | Synaptojanin-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis |
| Q36973350 | Synchronization of endothelial Dll4-Notch dynamics switch blood vessels from branching to expansion |
| Q39894670 | Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator |
| Q37796392 | Targeted therapies of cancer: Angiogenesis inhibition seems not enough |
| Q39858021 | Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity |
| Q52571053 | Targeting Notch signalling pathway of cancer stem cells. |
| Q26771701 | Targeting Notch to overcome radiation resistance |
| Q38135123 | Targeting angiogenesis and the tumor microenvironment |
| Q89953634 | Targeting angiogenesis in gastrointestinal tumors: current challenges |
| Q37563976 | Targeting angiogenesis: progress with anti-VEGF treatment with large molecules |
| Q37820099 | Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways |
| Q37696748 | Targeting notch signaling pathway in cancer: clinical development advances and challenges |
| Q37774852 | Targeting the ANGPT-TIE2 pathway in malignancy |
| Q38259982 | Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference |
| Q37234630 | Targeting the Notch1 and mTOR pathways in a mouse T-ALL model |
| Q37767356 | Targeting the tumour vasculature: insights from physiological angiogenesis |
| Q27001056 | Targeting γ-secretase in breast cancer |
| Q80212331 | The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth |
| Q28591594 | The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression |
| Q87907785 | The NOTCH Pathway in Head and Neck Squamous Cell Carcinoma |
| Q38564689 | The Notch pathway in colorectal cancer |
| Q36971953 | The Notch signaling pathway as a mediator of tumor survival |
| Q64244246 | The PERK Branch of the Unfolded Protein Response Promotes DLL4 Expression by Activating an Alternative Translation Mechanism |
| Q95642052 | The Role of DLLs in Cancer: A Novel Therapeutic Target |
| Q64958395 | The Role of Dll4/Notch Signaling in Normal and Pathological Ocular Angiogenesis: Dll4 Controls Blood Vessel Sprouting and Vessel Remodeling in Normal and Pathological Conditions. |
| Q41848212 | The STAT3-Ser/Hes3 signaling axis: an emerging regulator of endogenous regeneration and cancer growth |
| Q36677542 | The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. |
| Q40411894 | The Varied Roles of Notch in Cancer |
| Q41141631 | The Vascular Notch Ligands Delta-Like Ligand 4 (DLL4) and Jagged1 (JAG1) Have Opposing Correlations with Microvascularization but a Uniform Prognostic Effect in Primary Glioblastoma: A Preliminary Study |
| Q30499919 | The WNT antagonist Dickkopf2 promotes angiogenesis in rodent and human endothelial cells |
| Q38032676 | The abluminal endothelial membrane in neurovascular remodeling in health and disease |
| Q34075597 | The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation |
| Q91606602 | The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models |
| Q29547725 | The canonical Notch signaling pathway: unfolding the activation mechanism |
| Q38222770 | The challenge of targeting notch in hematologic malignancies |
| Q38654010 | The complex role of NOTCH receptors and their ligands in the development of hepatoblastoma, cholangiocarcinoma and hepatocellular carcinoma |
| Q26863506 | The critical roles of COUP-TFII in tumor progression and metastasis |
| Q38161389 | The dynamics of developmental and tumor angiogenesis-a comparison. |
| Q38685677 | The front and rear of collective cell migration. |
| Q34132722 | The functional role of Notch signaling in human gliomas |
| Q37702536 | The impact of the immune system on tumor: angiogenesis and vascular remodeling |
| Q37256458 | The many facets of Notch ligands |
| Q35852994 | The new era of the lymphatic system: no longer secondary to the blood vascular system |
| Q37780433 | The perivascular niche microenvironment in brain tumor progression |
| Q92263710 | The regulatory effect of microRNA-21a-3p on the promotion of telocyte angiogenesis mediated by PI3K (p110α)/AKT/mTOR in LPS induced mice ARDS |
| Q37991568 | The role of Adams in Notch signaling |
| Q41593423 | The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets |
| Q37694018 | The role of Notch signalling in ovarian angiogenesis. |
| Q36542074 | The role of extracellular matrix in vascular branching morphogenesis |
| Q27660544 | Therapeutic antibody targeting of individual Notch receptors |
| Q64130568 | Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma |
| Q52881532 | Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. |
| Q38208211 | Therapeutic modulation of Notch signalling--are we there yet? |
| Q40076736 | Therapeutic potential of novel modulators of neovascularization |
| Q38367121 | Therapeutic promise and challenges of targeting DLL4/NOTCH1. |
| Q92533654 | Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia |
| Q38268464 | Therapeutic vaccination targeting the tumour vasculature |
| Q91583689 | Thrombospondin 1 (THBS1) Promotes Follicular Angiogenesis, Luteinization, and Ovulation in Primates |
| Q35804895 | Thrombospondin-1 in a Murine Model of Colorectal Carcinogenesis |
| Q27335281 | Tipping the balance: robustness of tip cell selection, migration and fusion in angiogenesis |
| Q26863766 | Tips, stalks, tubes: notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis |
| Q37958944 | To sprout or to split? VEGF, Notch and vascular morphogenesis |
| Q35931463 | Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development |
| Q29614938 | Tumor angiogenesis |
| Q39393740 | Tumor angiogenesis revisited: Regulators and clinical implications. |
| Q91386068 | Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma |
| Q37606286 | Tumour-initiating cells: challenges and opportunities for anticancer drug discovery |
| Q37081884 | Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model |
| Q34972727 | Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer |
| Q57174401 | Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-angiogenic Therapy in Renal Cell Carcinoma |
| Q47140332 | Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy |
| Q38133568 | Understanding and targeting resistance to anti-angiogenic therapies |
| Q38219834 | Understanding the role of Notch in osteosarcoma |
| Q33422468 | Unique clonal relationship between T-cell acute lymphoblastic leukemia and subsequent Langerhans cell histiocytosis with TCR rearrangement and NOTCH1 mutation |
| Q37283444 | VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis |
| Q42099822 | VEGF and Notch in tip and stalk cell selection |
| Q42078015 | VEGF and endothelial guidance in angiogenic sprouting |
| Q33566710 | VEGF promotes cartilage angiogenesis by phospho-ERK1/2 activation of Dll4 signaling in temporomandibular joint osteoarthritis caused by chronic sleep disturbance in Wistar rats |
| Q37606226 | VEGF-VEGFR Signals in Health and Disease |
| Q36803200 | VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects |
| Q34791610 | VEGF-targeted therapy: mechanisms of anti-tumour activity. |
| Q33868524 | Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma |
| Q37076027 | Vascular Regeneration in Ischemic Hindlimb by Adeno-Associated Virus Expressing Conditionally Silenced Vascular Endothelial Growth Factor |
| Q30455612 | Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy |
| Q34759474 | Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma |
| Q37785877 | Vascular endothelial growth factor inhibitors in malignant gliomas. |
| Q34787476 | Vascular smooth muscle Notch signals regulate endothelial cell sensitivity to angiogenic stimulation |
| Q64074518 | Veins and Arteries Build Hierarchical Branching Patterns Differently: Bottom-Up versus Top-Down |
| Q59053661 | Vessel guidance |
| Q51738941 | Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch. |
| Q93076635 | What makes cells move: Requirements and obstacles for leader cells in collective invasion |
| Q36848635 | β -Elemene-Attenuated Tumor Angiogenesis by Targeting Notch-1 in Gastric Cancer Stem-Like Cells |
| Q35273488 | γ-H2AX promotes hepatocellular carcinoma angiogenesis via EGFR/HIF-1α/VEGF pathways under hypoxic condition |
| Q38766437 | γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct |
Search more.